Search results for "JANUS"

showing 10 items of 139 documents

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contribute…

2011

Signalling through the janus kinase (JAK)/signal transducer and activator of transcription (Stat) pathway is required at different stages of mammary gland development, and this pathway is frequently hyper-activated in cancer, including tumours of the breast. Stats 3, 5 and 6 have important roles in the differentiation and survival of mammary alveolar cells, but somewhat paradoxically, both Stat3 and 5 can have oncogenic activity in the mammary gland. Constitutive activation of JAK2 could be anticipated to result in hyper-activation of Stats 1, 3, 5 and 6 with concomitant cell transformation, although the outcome is difficult to envisage, particularly since Stats 3 and 5 play opposing roles …

MaleMammary glandTransplantation HeterologousMutation MissenseMice NudeBreast NeoplasmsMammary Neoplasms AnimalMiceMammary Glands AnimalPregnancyhemic and lymphatic diseasesCell Line TumormedicineSTAT5 Transcription FactorAnimalsHumansLactationSTAT3Mammary Glands HumanMolecular BiologySTAT5Mice KnockoutOriginal PaperJanus kinase 2biologyCell DeathCell growthCell BiologyJanus Kinase 2Enzyme Activationmedicine.anatomical_structureCell Transformation Neoplasticbiology.proteinSTAT proteinCancer researchFemaleSignal transductionJanus kinaseNeoplasm TransplantationSignal Transduction
researchProduct

The NK Cell Response to Mouse Cytomegalovirus Infection Affects the Level and Kinetics of the Early CD8+ T-Cell Response

2012

ABSTRACT Natural killer (NK) cells and CD8 + T cells play a prominent role in the clearance of mouse cytomegalovirus (MCMV) infection. The role of NK cells in modulating the CD8 + T-cell response to MCMV infection is still the subject of intensive research. For analyzing the impact of NK cells on mounting of a CD8 + T-cell response and the contribution of these cells to virus control during the first days postinfection (p.i.), we used C57BL/6 mice in which NK cells are specifically activated through the Ly49H receptor engaged by the MCMV-encoded ligand m157. Our results indicate that the requirement for CD8 + T cells in early MCMV control inversely correlates with the engagement of Ly49H. W…

MaleMuromegalovirusImmunologyNK cellsCD8-Positive T-LymphocytesBiologym157MicrobiologyRodent DiseasesMice03 medical and health sciencesInterleukin 210302 clinical medicineVirologyAnimalsCytotoxic T cellmouse cytomegalovirus; NK cells; T-cell response; Ly49H; m157IL-2 receptor030304 developmental biologyMice Inbred BALB C0303 health sciencesJanus kinase 3ZAP70BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Herpesviridae InfectionsNatural killer T cellMouse cytomegalovirus3. Good healthKiller Cells NaturalMice Inbred C57BLKineticsT-cell responseInsect ScienceImmunologyInterleukin 12CytokinesPathogenesis and ImmunityFemaleLy49HBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8030215 immunology
researchProduct

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report

2012

Abstract Background Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia. The activation of JAK2 and the increased levels of circulating proinflammatory cytokines seem to play an important role in the pathogenesis of myelofibrosis. Novel therapeutic agents targeting JAKs have been developed for the treatment of myeloproliferative disorders. Ruxolitinib (INCB018424) is the most recent among them. Case presentation To our knowledge, there is no evidence from clinical trials of an increased risk of tuberculosis during treatment with JAK inhibitors. Here we describe the first case of tuberculosis in a…

MaleOncologymedicine.medical_specialtyRuxolitinibTuberculosisSettore MED/17 - Malattie InfettiveAnemiaAntitubercular AgentsMyelofibrosislcsh:MedicineCase ReportGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineMyeloproliferative DisordersInternal medicineNitrilesmedicineHumansTuberculosisMyelofibrosislcsh:Science (General)lcsh:QH301-705.5Medicine(all)Janus kinase 2biologyLatent tuberculosisBiochemistry Genetics and Molecular Biology(all)business.industryTuberculosis Myelofibrosis Ruxolitiniblcsh:RGeneral MedicineJanus Kinase 2medicine.diseasePyrimidinesRuxolitiniblcsh:Biology (General)Primary MyelofibrosisImmunologybiology.proteinPyrazolesbusinessmedicine.druglcsh:Q1-390BMC Research Notes
researchProduct

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

2008

Abstract Objective: To analyse the effect of hydroxyurea (HU) on the JAK2-V617F allelic ratio (%JAK2-V617F) of patients with Polycythaemia Vera (PV) and Essential Thrombocythaemia (ET). Methods: Thirty-six patients were examined sequentially prior to and after on-set of (HU) therapy (8 PV, 17 ET), or while remaining untreated (2 PV, 9 ET). For all patients, the %JAK2-V617F was determined in purified blood granulocytes using sensitive allele-specific, quantitative PCRs. In a second study, two distinct groups of patients were examined at a single time point at the time of diagnosis (99 PV, 178 ET) or while receiving HU (36 PV, 98 ET). Results: HU therapy (median duration: 15 months) reduced t…

MalePediatricsmedicine.medical_specialtymedicine.drug_classImmunologyClone (cell biology)Allelic ratioBiochemistryAntimetaboliteGastroenterologyCohort StudiesHydroxycarbamidePolycythemia veraAntisickling Agentshemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedDNA PrimersRetrospective StudiesAged 80 and overJanus kinase 2HematologybiologyEssential thrombocythemiabusiness.industryCell BiologyHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurgeryAmino Acid SubstitutionMutationbiology.proteinFemalebusinessGranulocytesThrombocythemia Essentialmedicine.drugHaematologica
researchProduct

Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from…

2010

Abstract Ethnopharmacological relevance There is only scant literature on the anticancer components of medicinal plants from Nigeria, yet traditional healers in the area under study claim to have been managing the disease in their patients with some success using the species studied. Aim of study To document plants commonly used to treat cancer in South-western Nigeria and to test the scientific basis of the claims using in vitro cytotoxicity tests. Methods Structured questionnaires were used to explore the ethnobotanical practices amongst the traditional healers. Methanol extracts of the most common species cited were screened for cytotoxicity using the sulforhodamine B (SRB) assay in both…

MalePycnanthus angolensisEthnobotanyNigeriaPharmacognosyCajanusCajanusCell Line TumorNeoplasmsDrug DiscoveryMedicineHumansOleanolic AcidCytotoxicityMedicinal plantsPharmacologyPlants MedicinalbiologyTraditional medicinebusiness.industryData CollectionCancerPlantsbiology.organism_classificationmedicine.diseaseSitosterolsPlant LeavesAcanthospermum hispidumCancer cellEthnopharmacologyFlavanonesbusinessJournal of ethnopharmacology
researchProduct

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

2008

Background Many different techniques have been designed for the quantification of JAK2 V617F allelic burden, sometimes producing discrepant results. Design and Methods JAK2 V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specific primers or probes, or fluorescent resonance energy transfer/melting curve analysis), allele-specific polymerase chain reaction, conventional sequencing or pyrosequencing. Results A first series of blinded samples (granulocyte DNA, n=29) was analyzed. Seven assays (12 centers) reported values inside the mean±2SD; the mean coefficient of variation was 31%. Sequencing techniq…

MaleSerial dilutionPhenylalanineCoefficient of variationBiologyMelting curve analysislaw.inventionlawhemic and lymphatic diseasesTaqManHumansAllelesPolymerase chain reactionValineOriginal ArticlesHematologyJanus Kinase 2Molecular biologyPedigreePhenotypeReal-time polymerase chain reactionMutationPyrosequencingFemalePrimer (molecular biology)Thrombocythemia EssentialHaematologica
researchProduct

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus.

2020

An increased calcitonin serum level is suggestive of a medullary thyroid cancer (MTC), but is not pathognomonic. The possibility of false positives or other calcitonin-secreting neuroendocrine neoplasms (NENs) should be considered. Serum calcitonin levels are generally assessed by immunoradiometric and chemiluminescent assays with high sensitivity and specificity; however, slightly moderately elevated levels could be attributable to various confounding factors. Calcitonin values &gt;100 pg/mL are strongly suspicious of malignancy, whereas in patients with moderately elevated values (10–100 pg/mL) a stimulation test may be applied to improve diagnostic accuracy. Although the standard protoco…

MalediagnosisEndocrinology Diabetes and Metabolismbiomarkers; tumor; calcitonin; calcitonin gene-related peptide; carcinoma neuroendocrine; diagnosis differential; endocrine gland neoplasms; false positive reactions; female; humans; janus kinases; male; middle aged; reference values; sensitivity and specificity; thyroid neoplasmscarcinoma0302 clinical medicineEndocrinologyReference ValuehumansEndocrine Gland NeoplasmThyroidMedullary thyroid cancerGeneral MedicineFalse Positive Reactionreference valuesMiddle Agedmedicine.anatomical_structure030220 oncology & carcinogenesisFemalehormones hormone substitutes and hormone antagonistsHumanThyroid nodulesCalcitoninmedicine.medical_specialtytumordifferentialCalcitonin Gene-Related Peptide030209 endocrinology & metabolismNeuroendocrinologySensitivity and SpecificityDiagnosis Differential03 medical and health sciencesInternal medicinemedicineBiomarkers TumorneuroendocrineThyroid NeoplasmsCalcitonin Measurementbusiness.industryfalse positive reactionsbiomarkersCalcitonin secretionmedicine.diseaseCarcinoma NeuroendocrineEndocrinologyCalcitoninjanus kinasesJanus KinaseDifferential diagnosisendocrine gland neoplasmsbusiness
researchProduct

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

2009

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5…

Malemedicine.medical_specialtyPathologyLeukocytosismyeloproliferative neoplasm thrombosis jak2GastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeSettore MED/15 - Malattie Del SangueLeukocyte CountPolycythemia verahemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaLeukocytosisRisk factorProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedbusiness.industryEssential thrombocythemiaHazard ratioThrombosisHematologyGeneral MedicineJanus Kinase 2Middle Agedmedicine.diseaseThrombosisMultivariate AnalysisFemalemedicine.symptombusinessThrombocythemia Essential
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct